1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About NovoCure Ltd

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Asaf Danziger

No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700


NovoCure: See Past Market Myopia And Buy The Dip (NASDAQ:NVCR)
Sep 27, 2022 23:30pm

A conservative valuation of NovoCcure''s existing and expected future commercial pipeline suggests strong value accretion ahead. Click here to read more.

Source:Seeking Alpha
NovoCure Whale Trades For September 21
Sep 21, 2022 20:04pm

A whale with a lot of money to spend has taken a noticeably bearish stance on NovoCure . Looking at options history for NovoCure (NASDAQ: NVCR ) we detected 29 strange trades. If we consider the specifics of each trade, it is accurate to state that 3% of the investors opened trades with bullish expectations and 96% with bearish. From the overall spotted trades, 20 are puts, for a total amount of $693,844 and 9, calls, for a total amount of $732,700. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price … Full story available on Benzinga.com

Novocure creates new CNS focused franchise to renew growth in brain cancer business
Sep 21, 2022 13:14pm

Oncology company Novocure (NVCR) on Wednesday announced the creation of a central nervous system focused cancers franchise

Source:Seeking Alpha
NovoCure Stock: Does Reward Outweigh The Risk? (NASDAQ:NVCR)
Sep 09, 2022 04:01am

NovoCure has no competitors, has high earnings growth, almost $1B in cash and high gross margins. Read why I believe rewards outweigh the risks in NVCR stock.

Source:Seeking Alpha
Novocure to Participate in Upcoming Investor Conferences
Aug 31, 2022 12:00pm

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, as well as one-on-one meetings with investors

Why I Own Novocure Stock (NVCR)
Aug 22, 2022 14:15pm

Motley Fool contributor Brian Orelli shares why he loves this stock

Source:The Motley Fool